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N-glycosylation plays an important role in the majority of physiological and pathological processes occurring in the immune 
system. Alteration of the type and abundance of glycans is an element of lymphocyte differentiation; it is also common in the 
development of immune-mediated inflammatory diseases. The N-glycosylation process is very sensitive to different environmental 
agents, among them the pharmacological environment of immunosuppressive drugs. Some results show that high-mannose 
oligosaccharides have the ability to suppress different stages of the immune response. We evaluated the effects of cyclosporin 
A (CsA) and rapamycin (Rapa) on high-mannose/hybrid-type glycosylation in human leukocytes activated in a two-way mixed 
leukocyte reaction (MLR). CsA significantly reduced the number of leukocytes covered by high-mannose/hybrid N-glycans, and the 
synergistic action of CsA and Rapa led to an increase of these structures on the remaining leukocytes. This is the first study indicating 
that ß1 and ß3 integrins bearing high-mannose/hybrid structures are affected by Rapa and CsA. Rapa taken separately and together 
with CsA changed the expression of ß1 and ß3 integrins and, by regulating the protein amount, increased the oligomannose/hybrid- 
type N-glycosylation on the leukocyte surface. We suggest that the changes in the glycosylation profile of leukocytes may promote 
the development of tolerance in transplantation.
1. Introduction
Most cell surface and secreted proteins in the immune system 
are N-glycosylated [1- 4 ]. N-glycans added to the special pro­
tein sequence (Asn-X-Ser/Thr) during the posttranslational 
process form a large and important part of glycoprotein 
molecules; the oligosaccharide component reaches up to even 
50% of glycoprotein molecular mass [5]. N-glycoproteins 
contain three different oligosaccharide structures: high­
mannose, hybrid, and complex-type [6 ]. High-mannose gly- 
cans have been considered to be incomplete products of the 
N-glycosylation synthesis pathway, evolutionarily older than 
complex-type structures. They are thought to be typical for 
simpler organisms like yeast or fungi [5, 7 , 8], but some 
studies have shown that these oligosaccharide structures are
also abundant in mammalian cells and are no less important 
than completely processed complex-type sugar chains [9, 
10]. Recognition of high-mannose structures by mannose 
receptors in macrophages and dendritic cells is critical to 
the innate immune response responsible for elimination 
of bacteria and viruses and for initiation of organ-specific 
autoimmunity [11, 12]. Other work established that mannose- 
rich oligosaccharides can suppress the immune response [13], 
ligand binding [14], and intracellular signal transduction [15].
Integrins are transmembrane receptors which mediate 
adhesive events critical to an effective immune response 
[16- 19]. Leukocytes express a broad range of a ß  integrin 
heterodimers (at least 12) [17, 19]. The integrin repertoire 
on the leukocyte surface depends on the stage of leukocyte 
activation and is regulated by cytokines, chemokines, and
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other adhesion receptors [20 ]. The functions of leukocytes 
rely mostly on integrins belonging to the ß 2  fam ilybut also to 
the ß1 family 16], and ß3  integrins are important to leukocyte 
biology as well [19, 20 ]. They are also called very late antigens 
(VLA), because some integrins appear on the cell surface 
days or even weeks after leukocyte activation [21]. Integrins 
take part in the formation of immunological synapses [21, 
22], which serve immune cell communication [23]. These 
adhesion proteins are needed for leukocytes to move from 
the blood into peripheral tissues [20 , 24] and they mediate 
leukocyte interactions with endothelial cells and extracellular 
matrix proteins (ECM ) [20]. The most important integrins for 
leukocyte activation and migration are LFA-1 (aL ß2), a4ß\  
(VLA-4), and a 4 ß 7  [25- 27]. N-glycosylation of integrins, 
which are the highly N-glycosylated proteins, plays a crucial 
role in their functioning [28].
The proper functioning of immune cells in the response 
to alloantigens depends strongly on glycosylation of surface 
receptors [4 ]. Leukocytes modify cell interactions during 
each stage of the immune response by regulating the type 
and abundance of glycans; differentiation of leukocytes is 
also dependent on their glycosylation [8, 29- 31]. The N- 
glycosylation process is very sensitive to different environ­
mental agents and to the pathological conditions of immune 
diseases [29 , 32, 33]. In transplantation, strong inflammatory 
signals are induced in the recipient, which need to be 
controlled through administration of immunosuppressive 
drugs [34, 35].
We posited that the pharmacological environment of 
immunosuppressive drugs may modulate leukocyte glyco- 
sylation. To the best of our knowledge there are no pub­
lished studies evaluating the effects of cyclosporin A (CsA; 
inhibitor of calcineurin) and rapamycin (Rapa; inhibitor of 
mammalian target of rapamycin mTOR) on human immune 
cell glycosylation. In this study we assessed effects of these 
drugs on leukocyte glycosylation. These are immunosuppres­
sive agents commonly used to inhibit leukocyte activation 
during a rapid immune response. We found that CsA signif­
icantly reduces the number of leukocytes covered with high­
mannose/hybrid N-glycans, while the synergistic action of 
CsA and Rapa leads to an increase of these structures on the 
remaining leukocytes. We demonstrated, for the first time, 
that ß1 and ß3  integrins bearing high-mannose/hybrid struc­
tures are influenced by Rapa and CsA. Rapa taken separately 
and together with CsA significantly altered the expression of 
ß1 and ß3  integrins, and this caused an increase in the amount 
of oligomannose/hybrid N-glycans on leukocyte surfaces.
2. Materials and Methods
2.1. M aterials. Peripheral blood samples were obtained 
from healthy volunteers aged 18-60 years. Gradisol L 
was provided by Aqua Medica (Łódź, Poland). RPMI1640 
medium was purchased from Biomed, fetal calf serum 
(FCS), L-glutamine, and N-2-hydroxyethyl-piperazine-N7- 
2-ethanesulphonic acid (HEPES) from Gibco, and gen­
tamicin from Biochemie. Rapamycin and cyclosporin A 
were obtained from Wyeth-Lederle and Novartis Pharma,
respectively. Laemmli sample buffer (LSB, 161-0737) and 
ß-m ercaptoethanol (ß-M E) were from Bio-Rad and RIPA 
buffer (89900) and PageRuler Prestained Protein Ladder 
(26616) from Thermo Scientific. Biotinylated G alanthus 
nivalis agglutinin (GNA, B-1246), agarose-bound GNA (AL- 
1243), agarose-bound streptavidin (SA-5010), and Carbo­
Free Blocking Solution were obtained from Vector Lab. 
Mouse antibody against ß1 integrin subunit (MAB2251, 
clone B3B11), rabbit against ß3  subunit (AB1932), and 
alkaline phosphatase- (AP-) conjugated sheep anti-rabbit 
(AP322A) were obtained from Millipore. Rabbit poly­
clonal anti-GAPDH (G 9545), AP-conjugated goat anti­
mouse (084K4861) antibody, AP-conjugated ExtrAvidin 
(E2636), FITC-conjugated ExtrAvidin (E2761), Coomassie 
Brilliant Blue G (B2025), protease inhibitor cocktail (P2714), 
and trypan blue (T8154) were purchased from Sigma- 
Aldrich. Horseradish peroxidase- (HRP-) conjugated horse 
anti-mouse (7076S) and sheep anti-rabbit (70742) antibody 
were obtained from Cell Signaling Technology. Substrate for 
AP, nitro blue tetraźolium chloride (NBT) and 5-brom o-4- 
chloro-3-indolyl-phosphate (BCIP), and recombinant endo- 
ß-N-acetylglucosaminidase H (Endo H) from Streptomyces 
plicatus (11088726001) were purchased from Roche. Western 
Bright Sirius chemiluminescent HRP substrate (K-12043- 
D10) was obtained from Advansta.
2.2. M ixed Leu kocyte Reaction. Peripheral blood mononu­
clear cells (PBM Cs) were isolated from heparinized venous 
blood by density-gradient centrifugation over Gradisol L. 
PBM Cs were resuspended in RPMI1640 medium supple­
mented with 10% FCS, 20 mM  L-glutamine, 10 ^g/m L gen­
tamicin, and 1 M HEPES and counted in a hemocytometer 
chamber using trypan blue dye. Cells from two healthy 
donors (1 x 106 per 1 mL medium) were mixed 1: 1 for the two­
way mixed leukocyte reaction (MLR). The cells were cultured 
in 24-well plates at 37° C for 6 days in a C O 2 incubator (Lab 
Line Instruments) in the presence of CsA (200 ng per 1 mL 
medium), Rapa (20 ng per 1mL medium), and both drugs 
given together (150 ng CsA and 12 ng Rapa per 1 mL medium). 
The choice of immunosuppressive drug doses was based on 
earlier studies [36, 37].
2.3. F low  Cytom etric Analysis. The cells were harvested from 
M LR cell culture and washed twice in cold PBS. All the 
steps were performed on ice. Cells were incubated with 
biotinylated GNA (1:100) for 30m in  at RT, centrifuged 
(1800 rpm, 5m in , 4°C), and washed in PBS. Then the cells 
were incubated with FITC-conjugated ExtrAvidin (1 : 100) for 
30 min at RT and centrifuged under the same conditions as 
previously. After washing in PBS, fluorescence was measured 
by flow cytometry in a FACSCalibur (BD Biosciences) using 
Cell Quest software (BD Biosciences).
2.4. GNA Precipitation. Cell lysate proteins (500 ^g) were 
incubated with 25 ^L  agarose-bound G alanthus nivalis lectin 
(GNA) in HEPES buffer (10 mM  HEPES, pH 7.5, containing 
150 mM  NaCl) and incubated overnight at 4° C. After cen­
trifugation (14,000 rpm, 2m in , RT) the supernatants from
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the GNA-treated protein extracts were collected. The precip­
itates were washed three times in HEPES buffer and once 
in PBS. Glycoproteins were released from the glycoprotein- 
lectin-agarose complexes by boiling 10 min in 25 ^L  LSB 
containing ß-M E  at 100°C for 10 min. After final centrifu­
gation the supernatants containing GNA-positive glycopro­
teins were collected and destined for SDS-PAGE separation 
followed by M S/M S analysis.
2.5. Lectin  Blotting. GNA precipitates, the supernatant col­
lected after GNA precipitation, and cell lysate proteins were 
separated on 10% SDS-PAGE under reducing conditions and 
then transferred to a PVD F membrane. To detect proteins 
carrying high-mannose N-oligosaccharides, the PVD F blots 
were blocked in Carbo-Free Blocking Solution overnight at 
4°C. After washing three times in TBST and once in TBS with 
1 mM  M gCl2, 1 mM M nCl2, and 1 mM CaCl2, the membranes 
were incubated with biotinylated GNA lectin (1 : 4000) in 
TBS with the ions for 1h at RT. After further washing in 
TBST the membranes were incubated for 1 h at RT with 
AP-conjugated ExtrAvidin (1 : 4000). After final washing, 
the GNA-positive proteins were visualized using N BT/BCIP 
solution as substrate for AP.
2.6. M S/M S Analysis. GNA precipitates (20 ^L  from 25 
total volume) were separated by SDS-PAGE. The gel was fixed 
with 7% acetic acid in 40% methanol (v/v) for 30 min and 
stained with Coomassie Brilliant Blue for 2h . The gel bands 
corresponding to the GNA-positive proteins (separated on 
the same gel but destined for lectin reaction on a PVDF 
membrane; the 5 ^L  remainder from 25 ^L  total volume) 
were excised, subjected to trypsin digestion, and analyzed by 
tandem mass spectrom etry M S/M S in the Mass Spectrometry 
Laboratory of the Institute of Biochem istry and Biophysics, 
Polish Academy of Sciences (Warsaw, Poland). Proteins were 
identified by matching the peptides with the Sprot nonredun­
dant database (547357 sequences/194874700 residues) with 
a H om o sapiens  filter (20274 sequences) from the Mascot 
Distiller software (version 2.4.2.0, M atrixScience). Scores 
higher than 46 were considered to be significant (p  < 0.0005).
2.7. Endo H  Digestion. The content of high-mannose and 
hybrid glycans in integrin subunits was determined using 
endo-ß-N-acetylglucosaminidase H from Streptomyces p lica ­
tus. The cell glycoproteins (15 ^g) were suspended in sodium 
phosphate buffer (pH 5.5) to 50 mM final concentration. Pro­
tein denaturation was carried out in the presence of 0.2% SDS 
and 1 M ß-M E  for 3 min. After cooling to RT, 25 m U Endo H 
was added and the samples were incubated overnight at 37°C. 
The reaction was stopped by heating at 100°C for 10 min. Both 
digested and nondigested samples were boiled in LSB with ß- 
ME prior to SDS-PAGE on 10% polyacrylamide gels.
2.8. Im m unoblotting. Equal amounts of proteins in LSB with 
ß-M E  (15 ^g) were separated on 10% polyacrylamide gel 
and transferred to a PVD F membrane. After blocking in 1% 
BSA in TBST, integrin subunits were incubated for 1h at 
RT with anti-ß! and anti-^3 antibody diluted 1: 1000 in 1%
BSA in TBST. Rabbit anti-GAPDH IgG was diluted 1: 4000 
and incubated on a membrane in the same conditions. 
Then anti-mouse IgG and anti-rabbit IgG were applied in a 
1 :4 0 0 0  dilution and incubated at RT for 1 h. Integrin subunits 
were visualized by chemiluminescence in the GeneGnome 
Imaging System (Syngen) or with the colorim etric reaction by 
incubating the membranes with BCIP/N BT substrate for AP. 
The oligomannose/hybrid N-glycan amounts were calculated 
based on loss of molecular mass after Endo H digestion using 
UVImap Image Quantification software (UVItec).
3. Results
3.1. CsA Reduces GNA-Positive Cell Number, but the Syn­
ergistic A ction o f  CsA and  R apa Increases the A m ount o f  
GNA-Positive Glycoproteins. Glycosylation of alloantigen- 
activated PBM Cs from two individuals mixed together 
in two-way MLR cell culture was analyzed using FITC- 
labeled G alanthus nivalis agglutinin (GNA) in flow cytom­
etry. We found that the number of leukocytes covered by 
oligomannose/hybrid-type N-glycans decreased dramatically 
in the presence of CsA applied alone or with Rapa (Figure 1). 
Mean fluorescence intensity (M FI) was reduced slightly by 
the drugs given separately but the combination of both drugs 
significantly raised the M FI value. CsA was responsible for 
removal of high-mannose/hybrid N-glycans from the surface 
of over 60% of the leukocytes, but the synergistic effect of both 
immunosuppressive drugs markedly increased the amount of 
oligomannose/hybrid-type N-glycans on the remaining cells.
3.2. Glycoproteins B earing  H igh-M annose/H ybrid Structures 
A re A ffected by CsA an d R apa. Lectin blotting (LB) with 
biotinylated GNA disclosed changes in the oligomannose/ 
hybrid-type glycosylation of some proteins in samples with 
CsA given together with Rapa; the reaction was more intense 
in bands 1 and 2, while reduction of GNA binding was seen 
in band 3 (Figure 2(a)). Based on the GNA reaction, bands 
found to have been altered in intensity by immunosuppres­
sive agents were excised from the gels (Figure 2(b )) and their 
content was analyzed using M S/MS. This assay showed 62 
possible proteins in band 1,151 in band 2, and 126 in band 3. 
The ten identified proteins with the highest scores for each 
band are listed in Table 1. Among them are transmembrane 
proteins (ß  integrins, HLA class I histocompatibility antigen, 
LAMPs) and cytoplasmic proteins (enzymes of various 
metabolic pathways, coagulation factors). The molecular 
mass of the identified m onom eric glycoproteins, calculated 
based on the amino acid sequences, was lower than the mass 
determined in SDS-PAGE, due to the presence of N-glycan 
components. The theoretical molecular weight of multimeric 
glycoproteins is higher than that determined based on 
Protein Ladder standards, because the samples were resolved 
in reducing conditions.
3.3. Expression o f  ß1 Precursor an d  ß3  Integrin Subunits Is 
C hanged by CsA and  R apa. In further analyses we focused 
on the ß  integrin subunits identified in the band 1 to verify 
the results obtained by M S/M S analysis. Immunodetection



































F i g u r e  1: Immunosuppressive drugs alter the surface expression of high-mannose/hybrid N-glycans. Peripheral blood mononuclear cells were 
cultured for 6 days in the presence of CsA (200 ng per 1 mL medium), Rapa (20 ng per 1 mL medium), and the combination of CsA (150 ng 
per 1 mL medium) and Rapa (12 ng per 1 mL medium) in a two-way mixed leukocyte reaction (MLR). Immunosuppressive drug-treated and 
control cells were stained with biotinylated GNA (1: 100), followed by incubation with FITC-conjugated ExtrAvidin. M2 region corresponds 
to GNA-positive leukocytes after allostimulation. Fluorescence was measured using a FACSCalibur flow cytometer (BD Biosciences). C: 
untreated cells, CsA: cyclosporin A, and Rapa: rapamycin.
C
of the ß1 subunit after releasing the high-mannose/hybrid- 
type N-glycans with Endo H revealed that the ß1 precursor, 
with lower molecular mass, mainly carries these types of N- 
glycans (Figure 3), but the mobility shift in the control and 
immunosuppressive drug-treated M LR cells was comparable. 
Comparable loss o f molecular weight between the control and 
tested cells after Endo H digestion was also found in the ß3  
subunit. We observed, however, a significant increase o f the 
intensity o f the ß\ (both forms) and ß3  subunits in M LR cells 
cultured in the presence of Rapa alone or combined with 
CsA. GNA precipitation confirmed the results from Endo
H digestion of the ß l  subunit (Figure 4 ). GNA recognized 
mainly the ß1 precursor form; the mature subunit remained 
unprecipitated in supernatants. Here we also observed higher 
intensity of the ß1 subunit in M LR treated with Rapa and 
the combination of both drugs. ^ e s e  results indicate that 
high-mannose/hybrid-type glycosylation did not change on 
a single ß  integrin molecule but that the increased binding 
of GNA resulted from enhancement o f ß  integrin expression 
(Figures 3 and 4 ) and that it contributed to the overall increase 
of high-mannose/hybrid-type glycans on the cell surface in 
the presence of CsA and Rapa ( Figure 1).
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(a) (b)
F i g u r e  2: Immunosuppressive drugs change the intensity of bands containing GNA-positive proteins. Peripheral blood mononuclear cells 
were cultured for 6 days in the presence of the combination of CsA (150 ng per 1 mL medium) and Rapa (12 ng per 1 mL medium) in a 
two-way mixed leukocyte reaction (MLR) and then lysed in RIPA buffer. Whole-cell lysate proteins (500 ^g) were precipitated with 25 ^L 
agarose-bound Galanthus nivalis lectin (GNA). The captured glycoproteins were recovered by boiling in Laemmli sample buffer with ß-ME 
and resolved by 10% SDS-PAGE under reducing conditions. One-fifth of the GNA precipitate was destined for Western blotting (WB) and after 
probing with biotinylated-GNA was visualized by AP colorimetric reaction (a). The remaining four-fifths of the precipitate, after resolving 
on the same gel, were stained with Coomassie Brilliant Blue (CBB) and the bands were excised for MS/MS analysis (b). Molecular weight 
of proteins was assigned using a PageRuler Prestained Protein Ladder (Thermo Scientific, 26616). LP: lectin precipitation, C: untreated cells, 
CsA: cyclosporin A, and Rapa: rapamycin.
4. Discussion
It is well documented that immunosuppressive drugs, 
designed to inhibit activation o f the immune response [34], 
act by changing the expression of many proteins on immune 
cells [38- 4 0 ], including integrins [41- 4 4 ], but there are only 
few studies showing that they influence protein glycosylation 
[15, 45, 4 6 ]. For this reason we focused on determining 
the effects o f the immunosuppressive drugs CsA and Rapa 
on N-glycosylation of leukocytes alloactivated in vitro. Flow 
cytometric analysis showed that CsA downregulated the 
amount of GNA-positive leukocytes, but both drugs acting 
synergistically increased the surface expression of high- 
mannose/hybrid-type N-glycans on the remaining leuko­
cytes (Figure 1). Lectin blotting confirmed the enhancement 
o f the reaction with GNA lectin of some SDS-PAGE-resolved 
glycoproteins (Figure 2(a)). The synergistic effects o f CsA and 
Rapa, different from those of one-drug treatment, result from 
the various molecular mechanisms of these drugs [4 0 ]. They 
act at different stages of the T cell cycle: CsA at the G0 phase of 
the T lymphocyte cell cycle, and Rapa later at the transition 
from the G1 to the S phase. CsA interacts with calcineurin 
to block IL-2 gene transcription and then to inhibit T- 
cell proliferation, leading to decreased IL-2 production and 
secretion by T cells. Rapa blocks the intracellular signaling 
trigger by binding IL-2 to its receptor, thereby inhibiting T- 
cell responses to cytokines [38, 4 0 , 47]. Most protocols use 
a combination of agents for induction and maintenance of
immunosuppression to improve patient survival and graft 
survival rates and to reduce side effects [47 ].
In a proteomic study, Lee et al. [38] showed that 
most o f the altered proteins from human T lymphocytes 
treated with CsA and a polysaccharopeptide have functional 
significance in protein degradation, the antioxidant path­
way, energy metabolism, and immune cell regulation. Our 
M S/M S analysis revealed that among the human leukocyte 
glycoproteins affected by CsA and Rapa are HLA class I 
histocompatibility antigens (decreased reaction with GNA), 
enzymes of various metabolic pathways, coagulation factors, 
the adhesion protein LAMP1, and integrins of the ß1 and 
ß3  subfamilies (increased reaction with GNA) (Table 1). In 
further analyses we focused on the ß1 and ß3  integrin 
subunits. Immunodetection o f ß1 and ß3  subunits after 
Endo H digestion showed that the more intense reaction 
with GNA in Rapa- and Rapa/CsA-treated leukocytes was 
not the result o f changed oligomannose/hybrid glycosylation 
on these proteins, but rather increased expression of the 
integrins (Figure 3). Immunosuppressive agents usually act 
by decreasing protein expression, which leads to attenuation 
of the immune response and induces a state o f tolerance [ 40]. 
From previous results it is known that the changes in integrin 
expression caused by immunosuppressive drugs or blocking 
antibodies depend on the target cells and on the type and even 
the dose of agents. In a recent study, Zal et al. [4 4 ] observed 
reduction o f a2  and ß1 integrin expression on kidney fibrob­
lasts from CsA-treated rats. Sarnacki et al. [27] found that
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T a b l e  1: Cyclosporin A (CsA) and rapamycin- (Rapa-) affected GNA-positive glycoproteins identified by MS/MS. Proteins bearing high 
mannose/hybrid-type oligosaccharides expressed on MLR-activated leukocytes treated with a combination of CsA (150 ng per 1 mL medium) 
and Rapa (12 ng per 1 mL medium) were identified in MS/MS analysis by comparison of the results with the Sprot database. Ten glycoproteins 







Mass based Relative mass
Band no. Accession no. Protein name Mascotscore
on amino acid 
sequence 
[kDa]
calculated based on 
standard proteins 
[kDa]
P05106 Integrin beta-3 6117 145 34 90.2
P14625 Endoplasmin 692 27 23 92.6
P05556 Integrin beta-1 618 19 16 91.7
Q9NZ08 Endoplasmic reticulum 
aminopeptidase 1 321 8 8 100.0
P19367 Hexokinase-1 315 7 7 100.0
1 P11279 Lysosome-associated 
membrane glycoprotein 1 275 7 6 45.4 102.4
O00462 Beta-mannosidase 236 9 9 101.8
P12259 Coagulation factor V 226 6 6 252.7
Q99467 CD180 antigen 205 2 2 75.2
Q8TB96 T-cell immunomodulatory 
protein 124 3 3 68.5
P05164 Myeloperoxidase 2491 88 25 83.8
P07237 Protein disulfide isomerase 502 18 14 57.1
P51688 N-Sulphoglucosamine
sulphohydrolase 420 13 10 56.7
P16278 Beta-galactosidase 519 9 9 76.0
2 P00488 Coagulation factor XIII A 
chain 581 14 14 83.2 60.5
P01876 Ig alpha-1 chain C region 337 8 7 37.6
Q9Y4L1 Hypoxia upregulated protein 1 319 11 9 111.3
Q9NZK5 Adenosine deaminase CECR1 234 11 10 59.0
P08236 Beta-glucuronidase 208 6 5 74.7
Q9UHL4 Dipeptidyl peptidase 2 206 5 5 54.3
Q6P4A8 Phospholipase B-like 1 596 18 8 63.2
P15586 N-Acetylglucosamine-6-
sulfatase 287 9 5 62.0
O14773 Tripeptidyl-peptidase 1 250 6 4 61.2
P01889 HLA class I histocompatibility 
antigen, B-7 alpha chain 172 3 3 40.4
Q9BS26 Endoplasmic reticulum 
resident protein 44 166 5 5 46.9
3 Q07000 HLA class I histocompatibility 
antigen, Cw-15 alpha chain 121 3 3 40.8 42.6
P05121 Plasminogen activator 
inhibitor 1 
HLA class II
84 4 4 45.0
P04233 histocompatibility antigen 
gamma chain
76 1 1 33.5
P10314 HLA class I histocompatibility 
antigen, A-32 alpha chain 73 3 3 41.0
P09326 CD48 antigen 67 2 2 27.7
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F i g u r e  3: Rapamycin (Rapa) and the combination of cyclosporin A 
(CsA) and Rapa changes ß1 and ß3 integrin expression on MLR- 
activated cells. Peripheral blood mononuclear cells were cultured 
for 6 days in the presence of CsA (200 ng per 1mL medium), 
Rapa (20 ng per 1mL medium), and the combination of CsA 
(150 ng per 1mL medium) and Rapa (12 ng per 1mL medium) 
in a two-way mixed leukocyte reaction (MLR) and then lysed in 
RIPA buffer. Protein extracts (15 ^g) were digested with endo-ß- 
N-acetylglucosaminidase H (Endo H) from Streptomyces plicatus, 
SDS-PAGE-separated on 10% gel under reducing conditions, elec­
troblotted onto a PVDF membrane, and probed with specific pri­
mary antibodies: mouse monoclonal anti-^1 (Chemicon, MAB2251, 
clone B3B11) and rabbit polyclonal anti-^3 (Chemicon, AB1932). 
Antibody-bound integrins were visualized by chemiluminescence. 
GAPDH was the endogenous control. C: untreated cells.
F i g u r e  4: High-mannose/hybrid-type glycans are present mainly 
on premature ß1 integrin subunit. Cell lysate (L), glycoproteins 
precipitated with GNA-agarose (P), and supernatant collected after 
precipitation (S), containing proteins not recognized by GNA, 
were resolved on 10% SDS-PAGE gel under reducing conditions, 
electrotransferred to a PVDF membrane and destined for ß1 integrin 
subunit immunodetection. GAPDH was the endogenous control. C: 
untreated cells, CsA: cyclosporin A, and Rapa: rapamycin.
anti-LFA-1 protects against M HC-incompatible graft rejec­
tion of fetal small bowel grafts transplanted into mice, making 
this integrin a potential target for immunosuppression in 
intestinal transplantation. In turn, the effect o f the novel 
immunosuppressive drug mycophenolate mofetil (M M F) on 
tumor cells was dose- and cell line-dependent. In kidney 
carcinoma Caki I cells and pancreatic carcinoma DanG cells 
treated with 0.1 ^M  and 1 ^M  MMF, the expression of inte­
grins of the ß1 subfamily (a1ß1, a2ß1, a3ß1, a4ß1 , a5ß1, and 
a6ß1) was downregulated; in colonic adenocarcinoma HT- 
29, a3ß1, and a6ß1  integrins were upregulated in the presence 
o f 1 ^M  M M F; and in prostate carcinoma DU-145 most o f the 
analyzed integrins (a1ß1, a2ß\, a3ß\, and a5ß1) were upreg­
ulated under both M M F doses [41]. Dexamethasone (DEX),
a glucocorticoid used commonly for topical ocular applica­
tion, upregulated a v ß 3  integrin expression in the N27TM -2 
cell line derived from human ocular trabecular meshwork, 
due to an increase of both the half-life and transcription 
of ß3  integrin mRNA [42 ]. CsA also upregulated integrin 
ß3  expression but in a dose-dependent manner, resulting in 
enhanced murine embryonic adhesion and invasion, which 
promoted embryo implantation [43]. Our work also showed 
an increase o f ß1 and ß3  integrin expression in the presence 
o f a therapeutic dose of Rapa and under CsA and Rapa 
combined (Figures 3 and 4 ). An earlier study demonstrated 
that integrins ß1 and ß3  mediate adhesion of murine CD8+ 
cytotoxic T lymphocytes (CTL) to fibronectin (FN), which 
increased signal triggering by an association of proline-rich 
tyrosine kinase-2 (Pyk2) with paxillin and the Src kinases, 
resulting in M HC I-peptide-driven CTL degranulation [4 8 ]. 
ß1 and ß3  integrins participate in adhesion o f activated T cells 
to ECM  proteins upon TC R  triggering or, spontaneously, in 
secondary lymphoid organs or inflamed tissues, where they 
become highly exposed to ECM  proteins [48 , 4 9 ]. In this con­
text it is difficult to explain the increase of ß1 and ß3  integrin 
expression we observed upon immunosuppressive drug treat­
ment, but we note that the upregulation o f integrin expression 
was accompanied by an increase o f high-mannose/hybrid- 
type oligosaccharides on ß1 and ß3  integrins, as shown bythe 
reaction with GNA (Figure 2(a)). The total surface expression 
o f the high-mannose/hybrid-type N-glycans was also influ­
enced by the immunosuppressive drugs we used; the com bi­
nation of Rapa and CsA markedly increased the amount of 
those structures (Figure 1). Only a few previous studies have 
addressed the effect o f immunosuppressive agents on leuko­
cyte glycosylation. Paul et al. [4 6 ] showed that MM F inhib­
ited IL-1-induced expression of GNA-recognized oligosac­
charides with terminal mannose (Man) on rat endothelial 
cells. The ability o f M M F to downregulate glycosylation 
results from M M F inhibition o f inosine-monophosphate 
dehydrogenase, the enzyme that catalyses biosynthesis o f 
(deoxy) guanosine nucleotides necessary for transfer o f Man 
and fucose to glycoproteins [4 6 , 50 ]. M M F-induced reduc­
tion of the expression and glycosylation of some adhesion 
molecules decreases the recruitment o f lymphocytes and 
monocytes to sites o f inflammation and graft rejection [50 ]. 
Itraconazole (Ita), one of the mTOR inhibitors, reduced poly- 
N-acetyllactosamine and tetra-antennary complex-type N- 
glycans in human umbilical vein endothelial cells (HUVEC) 
and caused an increase o f Man5GlcNAc2 oligomannose 
structures on vascular endothelial growth factor receptor 2 
(VEGFR2). Hypoglycosylation ofV EG FR 2 strongly inhibited 
its autophosphorylation after VEGF stimulation [15]. Induc­
tion of hypoglycosylation on VEGFR2 in HUVEC cells by 
Ita was similar to the effects o f this drug in macrophages 
RAW 264.7. Glycosylphosphatidylinositol-anchored glyco­
protein CD14 in RAW 264.7 became Endo H-sensitive in 
the presence o f Ita. CD14 with altered glycosylation was 
delivered to the cell surface, as determined by binding of 
concanavalin A (Con-A) [51]. Alteration o f glycan synthesis 
by immunosuppressive drugs has also been observed in can­
cer cells. Treatment of MDA-MB231 breast cancer cells with 
Rapa upregulated the sialylation of N-glycans on ß1 integrin
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[45]. The clinically relevant concentration of CsA markedly 
decreased glucosylceramide levels in the multidrug-resistant 
human breast cancer M CF-7 cell line [52].
How does upregulation of GNA-positive glycoproteins, 
among the ß  integrins, driven by these anti-inflammatory 
immunosuppressive drugs, contribute to the development 
of immune tolerance against allogeneic antigens? We find 
a possible explanation in early studies by Muchmore et 
al. [13], which showed that mannose-rich oligosaccharide 
structures on uromodulin, ovalbumin, and soybean lectin 
(SBA ) directly inhibit the antigen-driven T  cell response in 
human mononuclear cell culture. W hat is more, treatment 
of endothelial cells with 1-deoxymannojirimycin (DM J) and 
castanospermine (CA ST), inhibitors which cause accumula­
tion ofhigh-m annose-type oligosaccharides, decreased inter­
leukin 1-induced lymphocyte binding to endothelial cells; 
reduction of lymphocyte extravasation results in suppression 
of the immune response [53]. Similarly, the presence of 
immature high-mannose oligosaccharides on both subunits 
of FN receptor, integrin a5ß1  in the cell surface of human 
fibroblasts, led to attenuation of ligand binding under treat­
ment with DMJ. Inhibition of oligosaccharide processing 
at the high-mannose N-glycan stage did not alter receptor 
assembly and insertion into the plasma membrane, but it 
significantly modified integrin binding ability [14]. What 
is interesting is that the content of immature N-glycans 
diminishes during lymphocyte maturation; half of the N- 
glycansonC D 45onthym ocytesare high-mannose or hybrid­
type, while the m ajority of N-glycans on CD45 on periph­
eral T cells are ST6Gal1-modified complex-type structures 
[30]. Conversion of high-mannose to complex-type N-linked 
glycans is also necessary for differentiation of human B 
lymphocytes into cells secreting immunoglobulins (Ig), as 
determined by strong inhibition of Ig production in culture of 
human lymphocytes with DM J or swainsonine (SW ), which 
block conversion of high-mannose to complex-type glycans 
[54]. On the other hand, activation of alloantigen-reactive 
regulatory T cells (Treg) resulted in increased expression of 
a1,2-mannosidase, the enzyme that catalyzes removal of Man 
from Man9GlcNAc2 and generates Man5GlcNAc2. In mice, 
reduction of high-mannose structures was not required for 
the suppressive capacity of Treg but facilitated its migration 
to sites where it regulates the immune response [35]. The 
divergence of these results may indicate that the glycan- 
mediated effect is specific to the T cell type or organism. 
In view of the above-mentioned studies, we suggest that the 
abundant high-mannose/hybrid-type glycans on ß1 and ß3  
integrins upregulated by CsA and Rapa may contribute to 
suppression of the immune response.
A variety of previous studies have shown that gly- 
cans play important roles in immune cell interactions dur­
ing the immune response [5, 8 , 33, 55], and now our 
results give further evidence that changes in oligosaccharide 
composition may shift the balance between the pro- and 
anti-inflammatory activities of leukocytes. Rapa and CsA 
have been shown to act synergistically for prolongation 
of allograft and xenograft survival [4 0 , 47 ]. Possibly the 
changes in the glycosylation profile of leukocytes promote the 
development of tolerance in transplantation. New approaches
aimed at developing better immunosuppressive strategies 
should incorporate the potential ability of drugs to alter 
glycosylation of target proteins.
5. Conclusions
Our study showed that these immunosuppressive drugs affect 
high-mannose/hybrid-type glycosylation of human leuko­
cytes activated in an MLR reaction. CsA significantly reduced 
the number of leukocytes covered by high-mannose/hybrid 
N-glycans, and the synergistic action of CsA and Rapa led to 
an increase of these structures on the remaining leukocytes. 
This is the first study indicating that ß1 and ß3  integrins 
bearing high-mannose/hybrid structures are affected by Rapa 
and CsA. By regulating the protein amount, the im m uno­
suppressive drugs increased the oligomannose/hybrid-type 
N-glycosylation on the leukocyte surface. This alteration of 
glycosylation on leukocytes may contribute to the develop­
ment of immune tolerance. The functional consequences of 
changes in the glycosylation profile are an area for further 
study.
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